

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2005/000461

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : G01N 33/50 G01N 33/92		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) SEE BELOW		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE BELOW		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, CAPLUS, WPIDS, BIOSIS: lipid, glycolipid, lysosomal, disorder, disease, Gaucher, Fabry, ratio, detect, diagnose		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Whitfield PD <i>et al</i> (2002) <i>Mol. Gen & Metabolism</i> 75: 46-55 "Correlation among Genotype, Phenotype and Biochemical Markers in Gaucher Disease: Implications for the Prediction of Disease Severity" Abstract, Fig 1 and Fig 3 Also cited by Applicants	1, 2, 4 - 16 & 23 -27
X	Cable WJL <i>et al</i> (1982) <i>Neurology</i> (Ny) 32: 1139-1145 "Fabry disease: Detection of heterozygotes by examination of glycolipids in urinary sediment" Abstract, Figure 2 and Table page 1143	1, 2, 4-8, 11-14, & 16-21
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 5 May 2005		Date of mailing of the international search report 19 MAY 2005
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer Philippa Wyrdean Telephone No : (02) 6283 2554

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU2005/000461

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2005/000461

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>Fujiwaki T <i>et al</i> (2002) <i>Brain & Development</i> 24:170-173 "Application of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in cultured skin fibroblasts from sphingolipidosis patients"</p> <p>Abstract, Figure 2</p>	1-9, 11, 13, 14-16, & 23-27
X	<p>Fujiwaki T <i>et al</i> (2002) <i>J. Chromatography B</i> 776: 115-123 "Application of delayed extraction-matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in pericardial fluid, peritoneal fluid and serum from Gaucher disease patients"</p> <p>Abstract, Figure 5</p>	1, 2, 4-9, 11-16 & 23-27
X	<p>Oshima M <i>et al</i> (1990) <i>Bloch et Biophys Acta</i> 1043: 157-160 "Urinary neutral glycosphingolipid analysis of patients with Fabry's disease; rapid isocratic elution from high-performance liquid chromatography as per-<i>o</i>-benzoyl derivatives"</p> <p>Abstract Table I</p>	1, 2, 4-8, 11, 13, 14, 17-21